Pharma supplier Lonza posts strong 3rd-qtr results
Pharmaceutical and biotech ingredient supplier Lonza (VTX: LONN) has posted a strong set of third-quarter 2016 financial results, and says it expects to hit its 2018 growth targets a year ahead of time.
The Swiss-based company pointed to continued strong performance in both its Specialty Ingredients and Pharma&Biotech segments, and was confident enough to say its earnings before interest and tax (EBIT) would likely cross the 15% growth line for full-year 2016.
Pointing to favorable economic conditions and anticipated growth, Lonza also said it expects to reach 1 billion Swiss francs ($1.01 billion) in CORE EBITDA (earnings before interest, tax, depreciation and amortization) and CORE RONOA (return on net operating assets) above 20% by the end of 2017, both one year ahead of time on its previous estimates.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Generics
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze